Glenmark Pharmaceuticals Opens Monoclonal Antibody Manufacturing Facility - - BioPharm International

ADVERTISEMENT

Glenmark Pharmaceuticals Opens Monoclonal Antibody Manufacturing Facility


Glenmark Pharmaceuticals, India, has opened a new cGMP-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.

Glenmark Pharmaceuticals' Swiss research center has in-house capabilities and infrastructure for conducting antibody discovery, cell-line development, in-vitro testing and characterization of antibodies, process development, and analytical research. The new manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade material. The manufacturing facility has been designed for use of single-use bioreactor systems and also houses a suite for manufacturing cell banks.

Source: Glenmark Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here